Cytokinetics' vendor botches ALS drug study
This article was originally published in Scrip
US biotech company Cytokinetics said a vendor bungled a Phase II trial by giving some patients placebo instead of the company’s experimental drug to treat ALS.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.